Samrat Pharmachem Ltd

Samrat Pharmachem Q3 FY2026 Results: Revenue Dips, Loss Reported 📊

• Revenue from operations for Q3 2025 was ₹6,342.61 lakhs, down from ₹7,887.03 lakhs in the previous quarter and similar to ₹6,366.12 lakhs in Q3 2024.

• Nine-month revenue for 2025 was ₹21,794.80 lakhs, slightly higher than ₹21,465.74 lakhs for the same period in 2024.

• The company reported a loss before tax of ₹56.71 lakhs for Q3 2025, compared to a profit of ₹391.26 lakhs in Q3 2024.

• For the nine months ended December 31, 2025, the company incurred a loss before tax of ₹110.77 lakhs, versus a profit of ₹1,024.96 lakhs in the same period last year.

• Basic earnings per share for Q3 2025 were negative at ₹(1.49), down from ₹9.01 in Q3 2024.